Literature DB >> 2474595

Different patterns of inositol polyphosphate production are seen in B lymphocytes after cross-linking of sIg by anti-Ig antibody or by a multivalent anti-Ig antibody dextran conjugate.

M Brunswick1, C H June, F D Finkelman, J J Mond.   

Abstract

Anti-delta antibody conjugated to 2 x 10(6) m.w. dextran (dex) stimulates B lymphocyte proliferation at 10,000-fold lower concentrations than that required by the unconjugated antibody. Dex conjugated antibody also stimulates a greater and more sustained increase in intracellular ionized calcium [( Ca2+]i) than does the unconjugated anti-Ig antibody. Inasmuch as inositol phosphate metabolites have been linked to rises in [Ca2+]i, we analyzed by FPLC the relative amounts of the inositol polyphosphates (IP) in these cells. Anti-Ig-dextran induced a threefold greater increase in total IP than did the unconjugated anti-Ig. Furthermore, in cells stimulated by unconjugated anti-Ig there was a transient induction of I(1,4,5)P3 followed by a rapid accumulation of the I(1,3,4)P3 isomer with little accumulation of I(1,4)P2, whereas in anti-Ig-dex-stimulated cells there was prolonged elevation of I(1,4,5)P3 with more accumulation of I(1,4)P2. In addition, levels of I(1,3,4,5)P4 were maintained over a longer period of time in B cells stimulated by anti-Ig-dex than in those stimulated by unconjugated anti-Ig. The enhanced ratio of I(1,4,5)P3/I(1,3,4)P3 was also seen when suboptimal concentrations of anti-Ig-dex were used which stimulated a level of total inositol phosphate that was similar to that stimulated by the unconjugated anti-Ig. The possibility that the greater stimulation of increased [Ca2+] by anti-Ig-dex than by unconjugated anti-Ig was a predominant factor in influencing the metabolic pathway of I(1,4,5)P3 was excluded. These results show that 1) stimulation of increases in the various IP isomers occurs in anti-Ig stimulated normal B cells as has been shown in B cell lines and 2) that signal transduction and consequent PIP2 hydrolysis that is stimulated by Ag-mediated cross-linking of sIg is strongly influenced by the extent and type of cross-linking that is induced.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474595

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Relationships between the degree of cross-linking of surface immunoglobulin and the associated inositol 1,4,5-trisphosphate and Ca2+ signals in human B cells.

Authors:  F M McConnell; S B Shears; P J Lane; M S Scheibel; E A Clark
Journal:  Biochem J       Date:  1992-06-01       Impact factor: 3.857

2.  Multiple isomers of inositol pentakisphosphate in Epstein-Barr-virus- transformed (T5-1) B-lymphocytes. Identification of inositol 1,3,4,5,6-pentakisphosphate, D-inositol 1,2,4,5,6-pentakisphosphate and L-inositol 1,2,4,5,6-pentakisphosphate.

Authors:  F M McConnell; L R Stephens; S B Shears
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

3.  Surface immunoglobulin crosslinking activates a tyrosine kinase pathway in B cells that is independent of protein kinase C.

Authors:  M Brunswick; L E Samelson; J J Mond
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

4.  Regulation of Alternative Oxidase Activity by Pyruvate in Soybean Mitochondria.

Authors:  D. A. Day; A. H. Millar; J. T. Wiskich; J. Whelan
Journal:  Plant Physiol       Date:  1994-12       Impact factor: 8.340

5.  Multilayer Control of B Cell Activation by the B Cell Antigen Receptor: Following Themes Initiated With Bill Paul.

Authors:  Anthony L DeFranco
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

6.  Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo.

Authors:  Yu Kato; Robert K Abbott; Brian L Freeman; Sonya Haupt; Bettina Groschel; Murillo Silva; Sergey Menis; Darrell J Irvine; William R Schief; Shane Crotty
Journal:  Immunity       Date:  2020-08-27       Impact factor: 43.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.